Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EQRX

EQRx (EQRX) Stock Price, News & Analysis

EQRx logo

About EQRx Stock (NASDAQ:EQRX)

Key Stats

Today's Range
$2.34
$2.34
50-Day Range
$2.04
$2.47
52-Week Range
$1.58
$5.55
Volume
N/A
Average Volume
3.30 million shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

EQRX Stock News Headlines

AUROW Aurora Innovation, Inc. WT EXP 110326
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
Rare "crisis signal" triggers for third time in U.S. market
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
See More Headlines

EQRX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that EQRx investors own include Meta Platforms (META), NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Exxon Mobil (XOM), CrowdStrike (CRWD) and General Electric (GE).

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:EQRX
Fax
N/A
Employees
362
Year Founded
N/A

Profitability

Net Income
$-169,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.40 per share

Miscellaneous

Free Float
398,218,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
0.48
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:EQRX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners